Preclinical evaluation of antidiabetic activity of noni fruit juice
Author(s): Puranik D. S., Mohammed Faraz, Nagaraju B*, Patan Fayaz, Nazeer Ahmed, Purohit Shanthraj, Ali Bolouri
Abstract
Diabetes mellitus (DM) currently is a major health problem for the people of the world and it is chronic metabolic disorder/ syndrome and the patients with DM experiences significant morbidity and mortality from micro vascular (Retinopathy, neuropathy, nephropathy) and macro vascular complications (Heart attack, stroke and peripheral vascular diseases). Because of frustration with conventional medicine and the desire to search for all possible resources to improve the chronic condition, patients with Diabetes mellitus generally adopts Complementary and Alternative Medicine (CAM) to assist them in coping with and controlling the disease. Noni (Morinda citrifolia L.) is used in Indian system of medicine for the treatment of variety of diseases and enriched with flavonoids, anthraquinone, glycoside and safe herbal drugs. Morinda citrifolia fruit juice has dose dependent activity and it was significant (p<0.001) decrease in blood glucose level at a dose of 1.8 and 3.6 ml/Kg, p.o., twice a day when compared with dexamethasone control. Further triglycerides were decreased in dose dependent manner and high dose has shown significant (p<0.05) decrease when compared to dexamethasone control. Morinda citrifolia fruit juice has not altered the dexamethasone induced catabolic effect. Morinda citrifolia fruit juice at high dose (3.6ml/Kg, p.o., twice a day) was found to be better than rosiglitazone. But at high dose Morinda citrifolia fruit juice has caused liver damage (micro vesicular steatosis) in rats. Morinda citrifolia fruit juice has shown hypoglycemic effect in normal rats. The above results indicate that the fruit juice is usefull in insulin resistance conditions. It was found that Morinda citrifolia fruit juice possesses hypoglycemic activity and can be used in diabetes.
Share this article
International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.
